Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
|Articles|November 1, 2003
Topping current ED therapies will be a major challenge
Author(s)John J. Mulcahy, MD, PhD
Now more than ever before, men suffering from erectile dysfunction havea high likelihood that their condition will be successfully managed. Withtwo efficacious, safe, and easily administered oral medications on the marketand a third coming soon, men with ED are far better off than they were just6 years ago.
Advertisement
Advertisement
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
Engy Habashy, MD, on the role of androgens in GSM management
5